Back to results
US 10,383,873 B2Granted
Method and kits for identifying of CDK9 inhibitors for the treatment of cancer
AssigneesMemorial Sloan Kettering Cancer Center, St. Jude Children's Research Hospital
InventorsScott William Lowe, Charles J. Sherr, Chun-Hao Huang, Amaia Lujambio
Life of this patent
Estimating the term…
Abstract
A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of MYC indicates a sensitivity to a treatment by a CDK9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and lymphoma.
Claims6
A method of treating a patient suffering from cancer, the method comprising the steps of:
- (a) determining whether MYC is overexpressed in a biological sample from the patient;
- and
- (b) administering to the patient an effective amount of a CDK9 inhibitor if MYC is found to be overexpressed in the biological sample in step (a), or administering a chemotherapeutic agent that is not a CDK9 inhibitor if MYC is not found to be overexpressed in the biological sample in step (a),
- wherein the cancer is selected from the group consisting of hepatocellular carcinoma, non-small cell lung carcinoma, leukemia, and lymphoma, and
- wherein the CDK9 inhibitor is not flavopiridol.
2 more elements
Dependencies are inferred from the claim text.